Kutatási jelek – Signal Engine

• Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma — Cholangiocarcinoma
• Behind the Paper: The Prognostic Impact of CXCR4 and TP53 Alterations on Zanubrutinib in Waldenström Macroglobulinemia — Waldenstrom macroglobulinemia
• World-first RNA discovery could lead to potential new breast cancer therapy — Breast cancer
• ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort — NSCLC
• Gastrointestinal stromal tumour – Trials in Disease – Overview of Information and Clinical Research — Gastrointestinal stromal tumor
• Endometrial cancer recurrent – Trials in Disease – Overview of Information and Clinical Research — Endometrial cancer
• Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma — Adrenocortical carcinoma
• Durvalumab extends survival in small cell lung cancer while raising critical cost‑effectiveness concerns — SCLC
• Treatment of Canine Metastatic Osteosarcoma with Combined Tumor Microenvironment Modification and Allogeneic Vaccination — Osteosarcoma
• A Phase 3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer — Cholangiocarcinoma
• Adjuvant Camrelizumab Plus Capecitabine in Intrahepatic Cholangiocarcinoma After Surgical Resection: Chinese Phase 2 Trial — Cholangiocarcinoma
• Hodgkin Lymphoma — Lung cancer
• Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer — Colorectal cancer
• A trial of mifamurtide for advanced osteosarcoma (MEMOS) — Osteosarcoma
• Frontline Osimertinib Combo Prolongs Survival in Advanced EGFR+ NSCLC — NSCLC
• Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer — NSCLC
• DAY301 | Day One Biopharmaceuticals — Adenoid cystic carcinoma
• High-grade B-cell lymphoma – Life with Disease – Overview of Information and Clinical Research — Lymphoma
• ECHO trial 50-month follow‑up results: ABR vs PBR in TN MCL — Lymphoma
• Delivering Immunotherapy for Head and Neck Squamous Cell Carcinoma in the Presence of Tumor Microbiome — Head and neck squamous cell carcinoma